ClinicalTrials.gg
RecruitingNCT06932081ACHIEVE-SGLT2iUpdated Feb 13, 2026

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

An observational study in Adult Congenital Heart Disease, Congenital Heart Disease and Systemic Right Ventricle, sponsored by Leiden University Medical Center. Recruiting at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Primary conditionTetralogy of FallotRegistry: Heart Defects, CongenitalReclassifiedWhy we changed it
Registry
Heart Defects, Congenital — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tetralogy of Fallot
Why
  1. The study's listed conditions name Tetralogy of Fallot, a narrower term within Heart Defects, Congenital.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Leiden University Medical Center · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Tetralogy of Fallot with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Tetralogy of Fallot · United States.

Planned enrollment
3rd of 12
400 · median 152
Started
2023
with 1 other
Observational
12 of 32
4 open now
Primary completion
2027-12
later than 9 of 11 live
Registered
30th of 32
by date

Among the 32 studies in Tetralogy of Fallot with a site in United States, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2023, is one of 12 observational ones, reaches primary completion later than 9 of the 11 other live ones, and was the 30th registered.

Tetralogy of Fallot

92 studies on the registry are indexed under Tetralogy of Fallot; 25 are open to participants now.

Browse Tetralogy of Fallot studies →

Open to participants now

7 of the 32 studies in Tetralogy of Fallot with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Tetralogy of Fallot studies recruiting now, 8 (47%) set no upper age limit and 9 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Tetralogy of Fallot with a site in United States, or all of them as a file.
02

Study summary

This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.

Read the detailed description

In the adult congenital heart disease (ACHD) population, heart failure currently represents the main cause of morbidity and mortality. The etiology of ACHD-related heart failure is heterogenous, and there is limited evidence for pharmacological treatment options for this population.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel pillar in the treatment of conventional LV heart failure. SGLT2i have been shown to reduce the risk of worsening heart failure and cardiovascular-related death in patients with LV heart failure.

While the exact mechanisms of action are still to be elucidated, SGLT2i seem to address heart failure by targeting several pathways. These include but are not limited to; a decrease in renin-angiotensin and sympathetic nervous system activation, a decrease in pressure overload-induced myocardial fibrosis, reverse cardiac remodeling, and improvement in myocardial energetics.

Given the compelling evidence on the effectiveness of SGLT2i over a broad range of cardiac dysfunction and initial promising reports of its utilization in the field of ACHD, SGLT2i deserve further exploration in the group of ACHD patients.

This real-world, international registry aims to evaluate the current experience with SGLT2i in ACHD patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.

Project design:

Data of all ACHD patients who were started on an SGLT2i will be collected in a real-world, international registry. Only data resulting from routine clinical care will be collected from the electronic health records at the participating centers, and participants will not undergo any interventions for this project. Data will be collected from 1 year before starting with the SGLT2i to most recent follow-up after starting with the SGLT2i, to evaluate if SGLT2i therapy halts the progression of clinical deterioration in ACHD patients with heart failure and can improve heart failure-related outcomes.

03

Conditions studied

  • Adult Congenital Heart Disease
  • Congenital Heart Disease
  • Systemic Right Ventricle
  • Transposition of the Great Arteries
  • Congenitally Corrected Transposition of the Great Arteries
  • Fontan
  • Single Ventricle
  • Tetralogy of Fallot (TOF)

Keywords

  • adult congenital heart disease
  • ACHD
  • congenital heart disease
  • CHD
  • sodium-glucose cotransporter 2 inhibitors
  • SGLT2i
  • SGLT2
  • heart failure
  • HF
  • transposition of the great arteries
  • TGA
  • systemic right ventricle
  • sRV
  • Fontan
  • single ventricle
  • tetralogy of fallot
  • ToF
04

In context

Tetralogy of Fallot Reclassified

92 studies on the registry are indexed under Tetralogy of Fallot; 25 are open to participants now.

This study's planned enrollment of 400 is above the median of 150 across 40 observational studies indexed under Tetralogy of Fallot.

Browse Tetralogy of Fallot studies →

Lead sponsor

Leiden University Medical Center is the lead sponsor of 334 studies on the registry; 110 are open to participants now.

Compared within Tetralogy of Fallot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Defects, Congenital. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adult patients (≥ 18 years) with congenital heart disease who have been treated with an SGLT2i are eligible for inclusion in the registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Congenital heart defect.
  • Age ≥ 18 years.
  • Initiated on treatment with an SGLT2i.

Exclusion criteria

Exclusion Criteria:

- No consent for data collection.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
400 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • ACHD patients treated with SGLT2i

    All participants included in the registry have to have a congenital heart defect, be ≥ 18 years old, and receive (or have received) treatment with SGLT2i.

    Drug: SGLT2 inhibitors

Interventions

  • Treatment with any type and dose of sodium-glucose cotransporter 2 inhibitor.

07

What researchers measure

Primary outcomes

  1. Prescription patterns

    The primary outcome of this registry is an overview of the prescription patterns of SGLT2i in the ACHD population.

    Time frame: Baseline information.

Secondary outcomes

  1. Side effects [Safety and Tolerability]

    Incidence and specification of any experienced side effects.

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  2. SGLT2i-related complications [Safety and Tolerability]

    Incidence and specification of any SGLT2i-related complications.

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  3. SGLT2i discontinuation [Safety and Tolerability]

    Incidence of any discontinuation of SGLT2i (including reason for discontinuation).

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  4. Mortality [Safety and Tolerability]

    Mortality and documentation of cause of death.

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  5. Admissions [Heart Failure-related Efficacy]

    Documentation of number of hospitalizations, including number of heart failure-related hospitalizations and number of urgent heart failure visits.

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  6. Clinical parameters - weight [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on weight (kg)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  7. Clinical parameters - systolic blood pressure [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on systolic blood pressure (mmHg)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  8. Clinical parameters - diastolic blood pressure [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on diastolic blood pressure (mmHg)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  9. Clinical parameters - heart rate [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on heart rate (beats per minute)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  10. Clinical parameters - saturation [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on oxygen saturation (%)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  11. Laboratory parameters - sodium [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on serum sodium (mmol/L)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  12. Laboratory parameters - potassium [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on serum potassium (mmol/L)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  13. Laboratory parameters - creatinine [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on serum creatinine (µmol/L)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  14. Laboratory parameters - eGFR [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on estimated glomerular filtration rate (eGFR, ml/min/1.73m2)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  15. Laboratory parameters - NT-proBNP [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on serum NT-proBNP (ng/L)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  16. Laboratory parameters - glucose [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on serum glucose (mmol/L)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  17. Laboratory parameters - HbA1c [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on serum HbA1c (mmol/mol Hb)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  18. Transthoracic echocardiography - LV function [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on systolic left ventricular (LV) function (categorical: good, mildly reduced, moderately reduced, severely reduced function)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  19. Transthoracic echocardiography - LV GLS [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on LV global longitudinal strain (GLS, %) assessed with transthoracic echocardiography

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  20. Transthoracic echocardiography - LV FAC [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on LV fractional area change (FAC, %) assessed with transthoracic echocardiography

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  21. Transthoracic echocardiography - RV function [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on systolic right ventricular (RV) function (categorical: good, mildly reduced, moderately reduced, severely reduced function) assessed with transthoracic echocardiography

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  22. Transthoracic echocardiography - RV GLS [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on RV GLS (%) assessed with transthoracic echocardiography

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  23. Transthoracic echocardiography - RV FAC [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on RV FAC (%) assessed with transthoracic echocardiography

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  24. Transthoracic echocardiography - RV S' [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on RV S' (cm/s) assessed with transthoracic echocardiography

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  25. Transthoracic echocardiography - TAPSE [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on tricuspid annular plane systolic excursion (TAPSE, mm) assessed with transthoracic echocardiography

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  26. Exercise parameters - 6MWT [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on exercise parameter 6-minute walk test (6MWT, meters)

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  27. Exercise parameters - maximum performance [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on maximum performance (Watt) with bicycle ergometry.

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  28. Exercise parameters - validity [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on validity (%-predicted of the maximum performance) with bicycle ergometry.

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  29. Exercise parameters - VO2 max [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on VO2 max (mL/kg/min) with bicycle ergometry.

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  30. Exercise parameters - %-predicted VO2 max [Heart Failure-related Efficacy]

    Evaluation of the longitudinal effect of SGLT2i on %-predicted of VO2 max (% of the VO2 max) with bicycle ergometry.

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

  31. Concomitant medication changes [Heart Failure-related Efficacy]

    Evaluation of the concomitant changes in other heart failure pharmacotherapy.

    Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.

08

Study locations

11 of 11 sites recruiting
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
    Recruiting
    • Ari M. Cedars, MD PhD · Principal investigator
  • Helen DeVos Children's Hospital
    Grand Rapids, Michigan 49503, United States
    Recruiting
    • Gruschen R. Veldtman, MBChB FRCP · Principal investigator
  • Mount Sinai Fuster Heart Hospital
    New York, New York 10029, United States
    Recruiting
    • Ali Zaidi, MD · Principal investigator
  • Heart Center Duisburg (Evangelical Hospital Niederrhein)
    Duisburg, Germany
    Recruiting
    • Paul Hacke, MD · Principal investigator
    • Anas Shihab, MD · Sub investigator
  • Leiden University Medical Center (LUMC)
    Leiden, South Holland 2333ZA, Netherlands
    Recruiting
    • Ralph M.L. Neijenhuis, MD · Contactr.m.l.neijenhuis@lumc.nl · +31 71 5262020
    • Björn N. Westdorp, MD · Contactb.n.westdorp@lumc.nl · +31 71 5262020
    • Anastasia D. Egorova, MD PhD · Principal investigator
    • Ralph M.L. Neijenhuis, MD · Sub investigator
    • Björn N. Westdorp, MD · Sub investigator
  • Amsterdam University Medical Center
    Amsterdam, Netherlands
    Recruiting
    • Berto J. Bouma, MD PhD · Principal investigator
  • University Medical Center Utrecht
    Utrecht, Netherlands
    Recruiting
    • Heleen B. Van Der Zwaan, MD PhD · Principal investigator
  • Zan Mitrev Clinic
    Skopje, North Macedonia
    Recruiting
    • Milka Klinceva, MD PhD · Principal investigator
  • University Hospital of Wales
    Cardiff, United Kingdom
    Recruiting
    • Simon T. MacDonald, MD DPhil · Principal investigator
  • Golden Jubilee University National Hospital
    Glasgow, United Kingdom
    Recruiting
    • Niki L. Walker, MBChB PhD · Principal investigator
  • Barts Heart Centre
    London, United Kingdom
    Recruiting
    • Filip Zemrak, MD PhD · Principal investigator
09

References and documents

Publications

  • Neijenhuis RM, Regeer MV, Walker NL, Mertens BJ, Hunter A, Kies P, Swan L, Vliegen HW, MacDonald ST, Zemrak F, Zaidi AN, Cedars AM, Jongbloed MR, Jukema JW, Veldtman GR, Egorova AD. Effect of sodium-glucose cotransporter 2 inhibitors on ventricular function in systemic right ventricular failure. Open Heart. 2025 Jul 21;12(2):e003445. doi: 10.1136/openhrt-2025-003445. PubMed 40695536 ↗
  • Neijenhuis RML, Regeer MV, Walker NL, Hunter A, Kies P, Holman ER, Jukema JW, Jongbloed MRM, Veldtman GR, Egorova AD. Echocardiographic effects of sodium-glucose cotransporter 2 inhibitors in single ventricle circulatory failure. Int J Cardiol Congenit Heart Dis. 2025 Jun 21;21:100603. doi: 10.1016/j.ijcchd.2025.100603. eCollection 2025 Sep. PubMed 40689152 ↗
  • Neijenhuis RML, MacDonald ST, Zemrak F, Mertens BJA, Dinsdale A, Hunter A, Walker NL, Swan L, Reddy S, Rotmans JI, Jukema JW, Jongbloed MRM, Veldtman GR, Egorova AD. Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease. J Am Coll Cardiol. 2024 Apr 16;83(15):1403-1414. doi: 10.1016/j.jacc.2024.02.017. Epub 2024 Mar 25. PubMed 38530688 ↗
  • Neijenhuis RML, Nederend M, Jongbloed MRM, Kies P, Rotmans JI, Vliegen HW, Jukema JW, Egorova AD. The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease. Front Cardiovasc Med. 2023 Jun 26;10:1093201. doi: 10.3389/fcvm.2023.1093201. eCollection 2023. PubMed 37435053 ↗
  • Egorova AD, Nederend M, Tops LF, Vliegen HW, Jongbloed MRM, Kies P. The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure. ESC Heart Fail. 2022 Jun;9(3):2007-2012. doi: 10.1002/ehf2.13871. Epub 2022 Mar 30. PubMed 35355435 ↗
  • Neijenhuis RML, Cedars AM, Zaidi A, Torres-Viera G, Mazurek R, Walker NL, Zemrak F, MacDonald ST, Hunter A, Kies P, Bosch L, Swan L, van der Zwaan HB, Jukema JW, Jongbloed MRM, Veldtman GR, Egorova AD. Real-world experience with sodium-glucose cotransporter 2 inhibitors in adults with Fontan circulatory failure. Front Cardiovasc Med. 2026 May 8;13:1771868. doi: 10.3389/fcvm.2026.1771868. eCollection 2026. PubMed 42181636 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2025
First posted
Apr 17, 2025
StartActual
Jan 1, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06932081
Responsible party
Anastasia D. Egorova, MD, PhD (Principal Investigator, Leiden University Medical Center) — Principal investigator
First posted
Apr 17, 2025
Start date
Jan 1, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Ralph M.L. Neijenhuis, MD
Contact
r.m.l.neijenhuis@lumc.nl
+31 71 5262020
Björn N. Westdorp, MD
Contact
b.n.westdorp@lumc.nl
+31 71 5262020
Anastasia D. Egorova, MD PhD
principal investigator · Leiden University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion